Looking Towards The Future of HR+/HER2- Breast Cancer
The expert panel discusses ongoing research and offers closing thoughts on the future of HR+/HER2- breast cancer treatment.
Practical Considerations for ADC Selection in HR+/HER2- mBC
Panelists share clinical insight into how to approach treatment selection among ADCs in HR+/HER2- metastatic breast cancer both now and in the future, given the currently available options and additional ADCs in development.
Data Updates on Sacituzumab Govitecan
Dr Gadi discusses recent data updates on the TROP-2–directed antibody-drug conjugate (ADC) sacituzumab govitecan (SG), including analyses performed in patients with HER2-low disease.
Biomarker Testing Practices in HR+/HER2- Breast Cancer
Experts on HR+/HER2- breast cancer discuss biomarker testing approaches, including sampling considerations and timing of testing.
HR+/HER2- Breast Cancer: Inhibiting the PI3K/AKT/mTOR Pathway
Dr Vidal expands on use of PI3K/AKT/mTOR pathway inhibitors following frontline progression, focusing on the PI3K inhibitor alpelisib for patients with PIK3CA mutations, as well as capivasertib, an AKT inhibitor in development.
Addressing Disease Progression on ET: Data Updates and Ongoing Trials
A focused discussion on trials that may address disease progression on first-line therapy, including those on ET and CDK4/6 inhibitor rechallenge and novel combination strategies.
Potential Approaches to Treatment Switching in HR+/HER2- mBC
Experts share how they approach management of patients with disease progression on first-line endocrine therapy, with a focus on ESR1 mutation testing and identifying who might be suitable for treatment with the oral SERD elacestrant.
Ribociclib/ET versus Chemotherapy in Premenopausal Patients: RIGHT Choice
Timothy Pluard, MD, discusses recent data from an age-based subgroup analysis of RIGHT Choice, which compares the efficacy of combination ribociclib/ET versus chemotherapy in the first-line treatment of HR+/HER2- advanced breast cancer.
The SONIA Trial: Exploring CDK4/6 Inhibitor Efficacy in the First- and Second-Line Settings
Gregory Vidal, MD, PhD, presents ASCO 2023 data from the SONIA trial, which assessed the efficacy of CDK4/6 inhibitors when given as part of a combination with endocrine therapy (ET) in either the first- or second-line setting.
Real-World Data on CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer and Ongoing Trials
Experts on HR+/HER2- breast cancer review recent real-world data on CDK4/6 inhibitors and share excitement about first-line trials that have not yet read out.
CDK4/6 Inhibitors in the Metastatic Breast Cancer Setting
The expert panel reviews CDK4/6 inhibitor options in the HR+/HER2- metastatic breast cancer (mBC) setting and previous data supporting their use.
Treatment and Dose Optimization in HR+/HER2- Early Breast Cancer
A comprehensive discussion on approaches to optimizing treatment selection and dosing in HR+/HER2- breast cancer.
Managing Abemaciclib-Associated Toxicities in HR+/HER2- Early Breast Cancer
VK Gadi, MD, PhD, shares his strategies for managing adverse events related to abemaciclib in the treatment of HR+/HER2- breast cancer.
Recent Data on Adjuvant Therapies in HR+/HER2- Breast Cancer
Experts on HR+/HER2- breast cancer review data updates on adjuvant therapies from the 2023 ASCO Annual Meeting.
Circulating Tumor DNA as a Prognostic Marker in HR+/HER2- Breast Cancer
A discussion on the use of circulating tumor DNA (ctDNA) as a prognostic biomarker in HR+/HER2- breast cancer.
Recent Data on Neoadjuvant Therapy in HR+/HER2- Breast Cancer
The expert panel reviews data updates on neoadjuvant therapy in HR+/HR2- early breast cancer and discusses the role of CDK4/6 inhibition in this setting.
Unmet Needs in Early-Stage HR+/HER2- Breast Cancer
Experts on HR+/HER2- breast cancer discuss unmet needs in the early-stage setting.
Standard-of-Care Treatment Approaches for HR+/HER2 Early Breast Cancer
A panel of expert oncologists review standard-of-care treatment approaches for HR+/HER2- early breast cancer and genetic testing practices when utilizing PARP inhibitors.
Dr Vidal on the Need for Improved Clinical Trial Representation in Breast Cancer
Gregory Vidal, MD, PhD, explains why clinical trials need to be more representative of the whole breast cancer population, in order to account for differences in biology and social determinants.
Dr. Vidal on the Role of Social Determinants of Health in Breast Cancer Care
Gregory Vidal, MD, PhD, discusses racial disparities in the treatment of patients with breast cancer.
Unmet Needs and Clinical Pearls for Metastatic Endometrial Cancer
Before closing out their conversation on endometrial cancer, Kathleen Moore and David O’Malley summarize unmet needs in the field and share a few clinical pearls on managing patients with the disease.
Emerging Biomarkers and Drug Targets in mEC
Shared insight into novel biomarkers and potential drug targets being explored for treatment of metastatic endometrial cancer.
Looking Towards the Future: Moving Targeted Therapies for mEC Into the First-Line Setting
Experts discuss ongoing clinical trials focused on moving second-line and higher targeted therapies, including immunotherapy, into the frontline setting for mEC, and then comment on how these advances might impact treatment paradigms and patient outcomes.
Considerations for Second-Line and Higher Treatment of Recurrent mEC
Drs Moore and O’Malley discuss the second-line and higher targeted treatment options that they’d consider for patients with mEC who develop recurrent disease on or after chemotherapy.
First-Line Therapy for dMMR mEC: Patient Conversations and Treatment Goals
Comprehensive discussion on patient counseling, and treatment goals, and expectations for those beginning first-line chemotherapy for dMMR metastatic endometrial cancer.
Biomarker Testing Standards-of-Care in Breast and Lung Cancer
The panel shares their recommendations for biomarker testing standard-of-care in breast cancer and lung cancer.
Monitoring Patients on First-Line Treatment for Metastatic Breast Cancer
Ellen Ball, ANP-FNP, reviews how patients are monitored for treatment response and toxicities during first-line treatment.
Expert Commentary on the Patient’s Treatment Plan
Expert oncologists discuss the patient’s first-line treatment plan and comment on how they would have approached her care.
A Review of mEC Incidence and Prognosis and Introduction of the Clinical Case
Drs Kathleen Moore and David O’Malley share their perspectives on the incidence and prognosis of mEC, including mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) disease, and then review a scenario of a patient with dMMR mEC who was treated with first-line carboplatin/paclitaxel.
Targeted Therapy in Metastatic Breast Cancer for Patients with BRCA Mutations
Key opinion leaders explain how early they introduce targeted therapy in mutated breast cancer.
Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care
Dr Habib on Developments in Palliative Care For Patients With Cancer
Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC
Dr In on the Increased Incidence of Gastric Cancer in Minority Patient Populations
2 Clarke Drive Cranbury, NJ 08512